Joseph A. DiGiuseppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph A. DiGiuseppe has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Jolene L. Cardinali
Hartford Hospital
4 shared publications- Katrina Collins
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
4 shared publications William N. Rezuke
Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut
3 shared publicationsBharat Ramlal
2 shared publicationsBradford J. Sherburne
Department of Pathology and Laboratory Medicine, Hartford Hospital, University of Connecticut School of Medicine, Farmington
2 shared publications- Dana Pe’er
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications
Latest Publications
- 1 October 2026
- Published by Springer Nature
- p. 127-144
Flow Cytometric Immunophenotyping of Acute Lymphoblastic Leukemia
- 1 October 2026
- Published by Springer Nature
- p. 127-144
Flow Cytometric Immunophenotyping of Acute Lymphoblastic Leukemia
- Open Access
- 31 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 121-123
MRD assessment by flow cytometry in B-ALL made easier
- 31 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 121-123
Open AccessMRD assessment by flow cytometry in B-ALL made easier
- 16 March 2022
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 102 (2) , 85-87
Issue Highlights—March 2022
- 16 March 2022
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 102 (2) , 85-87
Issue Highlights—March 2022
- Open Access
- 5 November 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 102 (2) , 168-170
CD4+ T‐cell large granular lymphocytic leukemia with STAT3 mutation and neutropenia
- 5 November 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 102 (2) , 168-170
Open AccessCD4+ T‐cell large granular lymphocytic leukemia with STAT3 mutation and neutropenia
- 1 March 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 100 (2) , 243-248
CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases
Background: CD49f (integrin alpha 6) is a useful marker for minimal residual disease (MRD) detection in B lymphoblastic leukemia and has recently been suggested to mediate infiltration of the central nervous system by leukemic B lymphoblasts. However, data regarding expression of CD49f protein in B lymphoblastic leukemia are limited, and whether CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia is unknown. Methods: CD49f protein expression was characterized by flow cytometry in a series of 40 cases of B lymphoblastic leukemia, which included the genetic subgroups: KMT2A-rerranged, BCR-ABL1+, ETV6-RUNX1+, hypodiploidy, and hyperdiploidy. Results: Expression of CD49f differed significantly among the five genetic subgroups studied, whether assessed by percentage of blasts positive for the antigen (p = .0001, Kruskal-Wallis) or median fluorescence intensity (MFI) (p = .0001, Kruskal-Wallis). Moreover, the percentage of CD49f+ blasts and MFI of CD49f were significantly lower in KMT2A-rearranged cases than in cases without KMT2A rearrangement (p = .0002 for both, Mann-Whitney). Conclusions: CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia, and is distinctly low in KMT2A-rearranged cases.
- 1 March 2021
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 100 (2) , 243-248
CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases
Background: CD49f (integrin alpha 6) is a useful marker for minimal residual disease (MRD) detection in B lymphoblastic leukemia and has recently been suggested to mediate infiltration of the central nervous system by leukemic B lymphoblasts. However, data regarding expression of CD49f protein in B lymphoblastic leukemia are limited, and whether CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia is unknown. Methods: CD49f protein expression was characterized by flow cytometry in a series of 40 cases of B lymphoblastic leukemia, which included the genetic subgroups: KMT2A-rerranged, BCR-ABL1+, ETV6-RUNX1+, hypodiploidy, and hyperdiploidy. Results: Expression of CD49f differed significantly among the five genetic subgroups studied, whether assessed by percentage of blasts positive for the antigen (p = .0001, Kruskal-Wallis) or median fluorescence intensity (MFI) (p = .0001, Kruskal-Wallis). Moreover, the percentage of CD49f+ blasts and MFI of CD49f were significantly lower in KMT2A-rearranged cases than in cases without KMT2A rearrangement (p = .0002 for both, Mann-Whitney). Conclusions: CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia, and is distinctly low in KMT2A-rearranged cases.
- 15 September 2019
- Published by Springer Nature
- Vol. 2032, 297-310
Immunophenotyping of Acute Lymphoblastic Leukemia
Immunophenotyping by flow cytometry is an important component in the diagnostic evaluation of patients with acute lymphoblastic leukemia. This technique further permits the detection of minimal residual disease after therapy, a robust prognostic factor that may guide individualized treatment. We describe here laboratory methods for both the initial characterization of lymphoblasts at diagnosis, and the detection of rare leukemic lymphoblasts after treatment. In addition to antibody combinations suitable for diagnosis and detection of minimal residual disease, we describe procedures for peripheral blood and bone marrow sample preparation, procedures for labeling of cell-surface and intracellular proteins with fluorochrome-conjugated antibodies, and approaches to analysis of immunophenotypic data.
- 15 September 2019
- Published by Springer Nature
- Vol. 2032, 297-310
Immunophenotyping of Acute Lymphoblastic Leukemia
Immunophenotyping by flow cytometry is an important component in the diagnostic evaluation of patients with acute lymphoblastic leukemia. This technique further permits the detection of minimal residual disease after therapy, a robust prognostic factor that may guide individualized treatment. We describe here laboratory methods for both the initial characterization of lymphoblasts at diagnosis, and the detection of rare leukemic lymphoblasts after treatment. In addition to antibody combinations suitable for diagnosis and detection of minimal residual disease, we describe procedures for peripheral blood and bone marrow sample preparation, procedures for labeling of cell-surface and intracellular proteins with fluorochrome-conjugated antibodies, and approaches to analysis of immunophenotypic data.
- Open Access
- 18 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7)
Front Cover
The cover image is based on the Clinical Image Intracytoplasmic crystalline inclusions in chronic lymphocytic leukemia by Bharat Ramlal and Joseph A. DiGiuseppe., DOI: 10.1002/ccr3.2250.
- 18 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7)
Open AccessFront Cover
The cover image is based on the Clinical Image Intracytoplasmic crystalline inclusions in chronic lymphocytic leukemia by Bharat Ramlal and Joseph A. DiGiuseppe., DOI: 10.1002/ccr3.2250.
- 24 June 2019
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 96 (4) , 256-265
Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma
In this review, we discuss applications of flow cytometric immunophenotyping (FCI) in the diagnostic evaluation and posttreatment monitoring of B and T lymphoblastic leukemia/lymphoma. We describe practical approaches to FCI at the time of diagnosis, with an emphasis on blast identification, lineage assignment, and distinction of B and T lymphoblastic leukemia/lymphoma from their morphologic and immunophenotypic mimics. We further review flow cytometric assays for the detection of minimal or measurable residual disease (MRD) after treatment, and illustrate both standard approaches, and newer strategies for improving sensitivity and circumventing the loss of immunophenotypic targets after immunotherapy. © 2019 International Clinical Cytometry Society
- 24 June 2019
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 96 (4) , 256-265
Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma
In this review, we discuss applications of flow cytometric immunophenotyping (FCI) in the diagnostic evaluation and posttreatment monitoring of B and T lymphoblastic leukemia/lymphoma. We describe practical approaches to FCI at the time of diagnosis, with an emphasis on blast identification, lineage assignment, and distinction of B and T lymphoblastic leukemia/lymphoma from their morphologic and immunophenotypic mimics. We further review flow cytometric assays for the detection of minimal or measurable residual disease (MRD) after treatment, and illustrate both standard approaches, and newer strategies for improving sensitivity and circumventing the loss of immunophenotypic targets after immunotherapy. © 2019 International Clinical Cytometry Society
- Open Access
- 13 June 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7) , 1460-1461
Intracytoplasmic crystalline inclusions in chronic lymphocytic leukemia
Neoplastic B cells may have cytoplasmic inclusions that are visible in routine peripheral blood smears by light microscopy.
- 13 June 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7) , 1460-1461
Open AccessIntracytoplasmic crystalline inclusions in chronic lymphocytic leukemia
Neoplastic B cells may have cytoplasmic inclusions that are visible in routine peripheral blood smears by light microscopy.
- Open Access
- 10 May 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (5)
Cover Image
The cover image is based on the Clinical Image Breast implant–associated anaplastic large‐cell lymphoma by Katrina Collins and Joseph A. DiGiuseppe, DOI: 10.1002/ccr3.2135.
- 10 May 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (5)
Open AccessCover Image
The cover image is based on the Clinical Image Breast implant–associated anaplastic large‐cell lymphoma by Katrina Collins and Joseph A. DiGiuseppe, DOI: 10.1002/ccr3.2135.